aimed analytics GmbH secures six-digit first funding and acquires ValueData GmbH

Bonn, September 2025 - aimed analytics GmbH has
successfully closed its first funding round, raising a six-digit
investment. At the same time, the company has completed
the acquisition of ValueData GmbH, further strengthening its
position as a pioneer in AI-driven biomedical data analytics.

"Our mission is clear: to shape the future of medicine
through the power of data analytics," says Dr. Patrick
Günther, CEO of aimed analytics. "The successful close of
this round is a strong validation of our vision and our team's
work."

The investors of this round include proMetis Consulting
GmbH, led by Dr. Guido Kemper, and Pi-Holding GmbH.
Both partners contribute not only capital but also valuable
expertise and strong networks to the company.

With the funding and the integration of ValueData GmbH,
aimed analytics aims to accelerate the development of its
self-service platform for omics data. The platform allows
researchers to analyze complex datasets from genomics,
transcriptomics, and epigenomics using natural language -
enabling faster, clearer decision-making in drug discovery
and biomedical research.

Beyond product development, aimed analytics will expand
collaborations with partners in pharma and academia and
strengthen its team.

aimed analytics GmbH
Presscontact: Jan Rudolph
Burbacher Str. 2
53129 Bonn
jan.rudolph@aimed-analytics.com

aimed analytics GmbH, based in Bonn, Germany, is developing an AI-powered self-service platform for analyzing complex omics data (e.g., genomics, transcriptomics, epigenomics). Researchers in biotech, pharma, and academia can pose questions in natural language and receive automated, reproducible, and actionable results. aimed analytics' mission is to accelerate biomedical research, enable new therapeutic approaches, and democratize data analytics in medicine.

This release was published on openPR.